Cord blood and cord tissue banking marketing: FDA status, use claims and obstetric office referrals

Expectant parents hear about cord blood banking from several directions at once: a brochure in the obstetric waiting room, a targeted ad in the third trimester, a registration kit offered at a prenatal visit, a hospital tour. Cord blood is a real transplant source with licensed uses, which is exactly why the marketing around it needs care. The gap between what cord blood is used for today and what a family might hope it could do one day is where the legal risk sits. This guide is for private and public cord blood banks, cord tissue banks, and the obstetric practices and birth centers that talk to parents about them.

Two related topics have their own guides and are not repeated here. Claims about stem cell and other regenerative treatments, FDA warnings and the court cases behind them are in our guide to stem cell clinic advertising. Privacy, tracking, birth stories and reviews for obstetric practices are in our guide to OB-GYN practice marketing.

What FDA says cord blood is and how it is regulated

FDA’s consumer page, Cord Blood Banking: Information for Consumers (dated July 23, 2012), describes cord blood as the blood in the placental blood vessels and umbilical cord, containing hematopoietic progenitor cells, which are blood-forming stem cells. It describes two banking options. Parents can donate to a public bank, where the cord blood is stored for potential use by anyone who needs it, or store it in a private bank for potential use by the child it came from or by first- or second-degree relatives.

The two options sit in different regulatory tiers. Under 21 CFR 1271.10(a), a human cell or tissue product is regulated solely under section 361 of the Public Health Service Act and Part 1271 only if it meets all of the listed criteria, including minimal manipulation, homologous use only, and, for a product with a systemic effect, use that is autologous, in a first- or second-degree blood relative, or reproductive. Establishments that make such products must register with FDA, list their products and comply with the rest of Part 1271. FDA’s consumer page says private cord blood stored for personal or family use that meets those criteria does not require approval before use, but private banks must still comply with registration and listing, donor screening and testing, reporting and labeling requirements and current good tissue practice. Cord blood stored for use in unrelated patients, as in public banks, must be licensed under a biologics license application or used under an investigational new drug application.

Two points from that page matter directly for marketing. First, FDA says registration does not mean a firm is endorsed by the agency; it means the firm has notified FDA that it performs one or more manufacturing steps. Second, FDA says registered establishments are subject to inspection, and that inspections of private banks are designed to ensure prevention of infectious disease transmission. Neither registration nor inspection is a finding that the bank’s product works for any use.

Registered is not approved: wording for FDA status

Because the tiers differ, the words do too. A private bank operating under section 361 and Part 1271 can accurately say it is registered with FDA, if it is. It should not say or imply that it, its process or its stored units are FDA approved, FDA licensed or FDA endorsed. A public bank holding a biologics license for its cord blood product can say its product is licensed by FDA for the licensed indication, and should not stretch that license to cover other uses or the bank’s private storage services, if it offers both.

FDA’s list of approved cellular and gene therapy products includes licensed HPC, Cord Blood products. The indication on one such product listing reads: for use in unrelated donor hematopoietic progenitor cell transplantation procedures in conjunction with an appropriate preparative regimen for hematopoietic and immunologic reconstitution in patients with disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment. That indication is about unrelated donor transplants from licensed public products. It is not evidence for a private bank’s claims about using a child’s own cord blood.

Homologous use is the other wording trap. 21 CFR 1271.3(c) defines it as the repair, reconstruction, replacement or supplementation of a recipient’s cells or tissues with a product that performs the same basic function in the recipient as in the donor. Section 1271.10(a)(2) says homologous use is judged as reflected by the labeling, advertising or other indications of the manufacturer’s objective intent. So a bank’s own advertising is part of the regulatory picture. Promoting stored cord blood or cord tissue for uses outside its basic function, such as treating conditions unrelated to blood formation, is a claim counsel should review for both FTC and FDA reasons before it runs.

Uses you can describe, and claims that go past the evidence

FDA’s consumer page says cord blood can be used in hematopoietic stem cell transplantation in patients with some disorders affecting the blood-forming system, and that cord blood transplants have been used to treat patients with certain blood cancers and some inherited metabolic and immune system disorders. It also says that for some diseases, such as genetically heritable diseases, a child’s own cord blood might not be recommended for treating that child.

ACOG’s Committee Opinion 771, Umbilical Cord Blood Banking (March 2019, reaffirmed 2026), states that cord blood collected from a newborn cannot be used to treat a genetic disease or malignancy in that same individual, because the stored cord blood contains the same genetic variant or premalignant cells that led to the condition. It states that there is no current evidence to support the use of an autologous cord blood sample in regenerative medicine, that the routine use of private cord blood banking is not supported by available evidence, and that public banking is the recommended method of obtaining cord blood. It also says the benefits and limitations of public versus private banking should be reviewed with the patient, and that collection should not compromise obstetric or neonatal care or alter routine practice of delayed cord clamping, with rare exceptions for directed donation.

Professional society positions are not law, but they shape what a reasonable parent would want to know, and they are the evidence an advertiser is measured against. Claims that need particular care:

• Lists of conditions “treatable with cord blood” that mix licensed transplant uses with research areas, without saying which is which or whether the list applies to the child’s own cord blood.
• Claims about future regenerative uses, such as treating brain injury, autism, diabetes or heart disease, presented as available or likely.
• Statements that a child’s own cord blood can treat that child’s genetic disease or leukemia, which ACOG states it cannot.
• Odds of use, match rates or numbers of transplants without a current, cited source that matches the claim.
• Cord tissue claims. Cord tissue is a different product from cord blood. Any claim about future treatment uses of stored cord tissue is a health claim that needs its own evidence, and our stem cell guide covers how FDA and the FTC treat regenerative claims.

Biological insurance and other framing claims

Section 5 of the FTC Act, 15 U.S.C. 45, prohibits deceptive acts or practices, and 15 U.S.C. 52 prohibits false advertisements for services, among other things. The FTC’s Health Products Compliance Guidance (December 2022) applies those sections to health claims and says health-related claims require substantiation in the form of competent and reliable scientific evidence, judged by the net impression of the whole ad.

“Biological insurance,” “once-in-a-lifetime protection,” “your baby’s personal stem cell supply” and similar phrases are framing claims. They do not name a disease, but they convey that stored cord blood is likely to be useful to this family and that not banking leaves the child unprotected. Under the net impression test, that message needs the same support as an express claim. Given FDA’s note on genetically heritable diseases and ACOG’s statements on autologous use, a bank should be able to show evidence for whatever level of future benefit its framing implies, or change the framing. Fear-based copy aimed at parents in late pregnancy, such as messages implying a parent who does not bank has failed the child, can add to the net impression the FTC looks at.

Safer framing describes the service, not a promise: what is collected, how it is processed and stored, which uses are established today, what is under research, how public donation differs, and what the family pays. A side-by-side comparison of public donation and private storage, written in plain language, answers the question ACOG says should be discussed and is honest marketing at the same time.

Prices, storage terms and the fine print

Parents compare banks on price and storage terms, so those claims are part of the net impression too. State the full cost of collection, processing and the first storage period, the recurring storage fee, what happens if a payment is missed, what happens to a unit if the bank closes or is sold, and what the family gets back if a unit cannot be stored because the sample was too small or failed testing. FDA’s consumer page notes that private bank units are tested for infectious diseases; if a unit can be discarded for a test result, say so before the family signs. Avoid “free” or “no cost” collection offers unless every condition of the offer is stated clearly up front.

Obstetric practices: referral payments and endorsements

Cord blood banks reach parents through the clinicians who see them, and that is where referral law comes in. The federal anti-kickback statute, 42 U.S.C. 1320a-7b(b), makes it a felony to knowingly and willfully offer, pay, solicit or receive any remuneration to induce or reward referrals of items or services payable in whole or part by a federal health care program. Private cord blood storage may be paid by the family, but obstetric practices and hospitals also bill federal programs for the care around the birth, and whether a particular arrangement touches federal program business is a fact question for counsel. State anti-kickback and fee-splitting laws are set state by state, and counsel should check whether they reach payments no matter who pays for the service.

Arrangements to send to counsel before signing:

• Per-enrollment or per-collection payments from a bank to a practice, clinician or staff member, beyond fair payment for collection work actually performed.
• Free or discounted storage for the practice’s clinicians or staff, gift cards, meals, trips or marketing funds tied to enrollments.
• Revenue sharing between a practice and a bank, or a practice ownership interest in a bank it recommends.
• Bank representatives placed in the office or on the labor floor, paid by the bank, who also do work the practice would otherwise pay for.

Endorsements are a second issue. If a practice or clinician recommends a bank and has a financial relationship with it, the FTC Endorsement Guides at 16 CFR 255.5 call for clear and conspicuous disclosure of a material connection that the audience would not expect. A waiting room brochure stand stocked by one bank, with the practice’s logo on the brochure, reads as a recommendation. If the practice prefers to stay neutral, it can offer balanced information on public donation and private storage, and leave the choice of bank to the family.

Patient lists and HIPAA marketing rules

A bank cannot get a list of expectant patients from an obstetric practice for its own marketing just because the two have a referral relationship. Under 45 CFR 164.501, a communication encouraging patients to buy a third party’s product or service is marketing, subject to listed exceptions, and the exceptions do not cover communications for which the covered entity receives financial remuneration from the third party whose product is described. Under 45 CFR 164.508(a)(3), a covered entity must obtain the patient’s authorization for any use or disclosure of protected health information for marketing, with limited exceptions, and where the marketing involves financial remuneration to the covered entity from a third party, the authorization must say so. That covers sharing due dates or contact details with a bank, and mailing a bank’s offer to patients when the bank pays for the mailing.

Public donation is part of honest marketing

FDA’s consumer page tells parents that donating to a public bank makes cord blood available to anyone who needs a transplant, and it points to the federal government’s information on donation. ACOG recommends public banking as the way to obtain cord blood. A private bank does not have to promote its competitors, but a page that compares only private banks and leaves out public donation omits the option the medical society recommends. A short, accurate section on public donation, with a link to federal information, answers the obvious question a parent will ask their obstetrician anyway. Practices that discuss cord blood can do the same, and check whether their state requires specific information to be given to patients.

Illustration: two ways to market private cord blood storage

Illustration: [Bank name] runs a third-trimester ad that reads “Biological insurance for your baby’s future. FDA registered. Treats [number] conditions.” The landing page lists conditions without separating licensed transplant uses from research, mentions no limitations on use for the child’s own genetic conditions, and offers the obstetric practice a fee for each family that enrolls through its code. The ad’s net impression overstates future benefit, “FDA registered” next to a treatment claim reads as FDA approval, the conditions list has no source, and the referral fee needs counsel review before anyone signs.

Illustration: [Bank name] runs an ad that reads “Questions about cord blood? Compare public donation and private storage before your due date.” The page explains what FDA registration means and does not mean, quotes the established transplant uses, states that a child’s own cord blood cannot treat that child’s genetic disease, links ACOG’s committee opinion and federal donation information, and lists every fee and storage term. Obstetric offices receive the same neutral handout as any other patient material, with no per-enrollment payment.

Checklist

• Describe FDA status in the right tier: registered for section 361 private banking, licensed only for licensed products and indications.
• Never use FDA approved, FDA licensed or FDA endorsed for a private bank’s process or stored units.
• Separate established transplant uses from research and from claims about a child’s own cord blood.
• Remove claims that a child’s own cord blood treats that child’s genetic disease or leukemia.
• Support any framing claim, such as biological insurance, with evidence for the level of benefit it implies, or replace it.
• Treat cord tissue claims as separate health claims that need their own evidence.
• Show all fees, storage terms, unit failure rules and what happens if the bank closes or is sold.
• Send any payment, discount or gift between a bank and a practice or its staff to counsel.
• Disclose material connections when a practice or clinician recommends a bank.
• Get HIPAA marketing authorization, with remuneration disclosed, before any patient data or paid mailing reaches a bank.
• Include accurate information on public donation.

How we help

We build websites, local search, Google Ads and AI front desk tools for independent practices and health businesses. For cord blood banking, that means comparison pages and service pages that state FDA status and established uses accurately, ad copy without insurance-style promises, and inquiry forms that do not pull patient data from obstetric offices. We do not decide whether a product is regulated under section 361 or whether a payment fits referral law; your counsel does. Our tools are built with HIPAA in mind. We confirm in writing what a BAA covers before any patient information flows through a tool, and if it is not covered, we do not route patient information through it. We are not a healthcare provider and we do not give legal or medical advice. We do not sell lead lists and we do not pay for referrals. For the wider rules, see our healthcare marketing rules hub.

Sources

• FDA: Cord Blood Banking, Information for Consumers (July 23, 2012)
• FDA: Approved cellular and gene therapy products
• FDA: Licensed HPC, Cord Blood product listing
• 21 CFR 1271.3: How does FDA define important terms in this part?
• 21 CFR 1271.10: HCT/Ps regulated solely under section 361 of the PHS Act
• ACOG Committee Opinion 771: Umbilical Cord Blood Banking (March 2019, reaffirmed 2026)
• FTC: Health Products Compliance Guidance (December 2022)
• 15 U.S.C. 45: Unfair methods of competition and unfair or deceptive acts or practices
• 15 U.S.C. 52: Dissemination of false advertisements
• 16 CFR 255.5: Disclosure of material connections
• 42 U.S.C. 1320a-7b: Criminal penalties for acts involving Federal health care programs
• 45 CFR 164.501: Definitions
• 45 CFR 164.508: Uses and disclosures for which an authorization is required

More in Health companies, vendors and employers